Opinion|Videos|July 19, 2024

ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

Name: ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone
Uploaded: 2024-07-19T19:50:00.000Z
Duration: 6 min 5 s
Description: ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

Author(s)Alfred L. Garfall, MD

Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024.

Video content above is prompted by the following questions:

Discuss the data presented at ASCO 2024 on the DREAMM-8 study (NCT04484623) of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). (Abstract)
1. What was the objective of this study?
2. How was this study designed/what methodology was used?
3. What results were presented?
  1. N=155
  2. Median follow-up: 21.78 months
  3. PFS
  4. ORR
  5. Median duration of response
  6. OS
  7. Safety
Please provide your key takeaways from this study.How might these findings impact the management of patients with RRMM?
Belantamab mafodotin was previously withdrawn from the US market for RRMM following results from the phase 3 DREAMM-3 trial (NCT04162210) which did not meet its primary endpoint of progression-free survival (PFS). How do the results of the DREAMM-8 trial shed light on potential advantages of BPd in patients with RRMM?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Latest CME

AJMC Supplement

Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia

3.0 Credits / Psychiatry

ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

Newsletter

Related Content

Teclistamab for R/R MM Effective and Safe When Administered in a Community Setting

Early Linvoseltamab Use Prevents Myeloma Progression: Paula Rodríguez-Otero, MD, PhD

Navigating Cilta-Cel Sequencing in Multiple Myeloma: Surbhi Sidana, MD, MBBS

Value-Based Myeloma Care Amid Game-Changing Therapeutic Developments: Matias Sanchez, MD

Vaccination Remains Essential in Multiple Myeloma Despite Impaired Responses

Latest CME

Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia

From Strict Avoidance to Tailored Therapies: Transforming Food Allergy Care

The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes

Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies

Closing Gaps in CLL Care: Managed Care Insights and Strategies

Revolutionizing Acute Pain Relief: Emerging Non-Opioid Therapies and the Essential Role of Pharmacists

Overview and Burden of Migraine

The Role of the Pharmacist Migraine Management

The Evolving Treatment Landscape of Migraine

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

New and Approved: FDA’s 2024 Drug Lineup

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Leveraging Managed Care to Optimize Patient Outcomes: Integrating Novel Treatments in Schizophrenia

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

Optimizing the Uptake of Long-Acting Injectables in HIV Treatment and Prevention: Considerations for Managed Care

Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Managed Care

Navigating the Advancements in Oral Therapy Options in HR+ Metastatic Breast Cancer

Navigating the Changing Treatment Paradigm of Metabolic Dysfunction-Associated Steatohepatitis: A Guide for Managed Care Pharmacists

Managed Care Approaches and Models for Equitable Access to Innovations in Major Depressive Disorder Treatment

Evaluating the Effectiveness and Value of Novel Nonhormonal Treatments in the Management of Menopause-Related Vasomotor Symptoms

Updated Guidance and Managed Care Strategies to Optimize Respiratory Syncytial Virus Vaccination Coverage

Leveraging Biologics and Immunotherapies in the Management of Food Allergies

Advancing Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Optimizing Outcomes With Emerging Therapies

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

Reflecting on the Real-World Use of Biologic Therapy in Asthma Management

Advancing Cystic Fibrosis Management: The Evolving Role of Specialty and Managed Care Pharmacists

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

Targeting Chronic Rhinosinusitis With Nasal Polyps With Biologics: Optimizing Outcomes and Reducing Health Care Burden

Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition

Transforming Metabolic Dysfunction-Associated Steatohepatitis Management: Pharmacist Considerations for the Evolving Treatment Landscape

Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches

The Expanding Therapeutic Landscape in IgA Nephropathy: Applying Evidence-Based Strategies and Guideline Updates for Managed Care

Leveraging Novel Therapies to Transform Demodex Blepharitis Care (Pharmacy Technician Credit)

Leveraging Novel Therapies to Transform Demodex Blepharitis Care

The Changing Paradigm in Pain Management and Supporting Access to Novel Therapies

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

Opioids, Pain Management, and Substance Use Disorder: A Practical Overview

Trending on AJMC

Dual JAK Inhibition Demonstrates Efficacy in Progressive Nonsegmental Vitiligo

Nerandomilast a "No-Brainer" for First-Line Pulmonary Fibrosis Therapy: Justin M. Oldham, MD, PhD, MS

FDA Grants Breakthrough Therapy Designation to R-DXd in CDH6-Expressing Ovarian Cancer

FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis

Science Under Attack: Experts Warn of Rising Threats to Research Integrity